Clinical Trials Logo

Clinical Trial Summary

This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive); each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.

Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events.

This study is expected to be completed in a period of 3 years.


Clinical Trial Description

Depression and dementia are the two common psychiatric disorders in the elder subjects. Alzheimer's disease (AD) is the most frequent cause of dementia and about 20% of them have depression. Depression subjects are associated with more rapid cognitive decline, a poorer response to treatment. Post mortem study showed close relationship between AD and disruptions of the serotonergic system, including loss of serotnergic neurons at brain stem. However, the alternations in presynaptic serotonin function relative to demented or non-demented subjects remain to be investigated in living subjects. In this study, the investigators will collect 40 elder subjects (i.e., age above or equal to 50 years old). The serotonin transporter activity will be compared between subjects with or without dementia using I-123 ADAM images. The single photon emission tomography (SPECT) will be compared to recent (within 6 months) F-18 FDG PET images for further investigation. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


NCT number NCT01548937
Study type Interventional
Source Chang Gung Memorial Hospital
Contact
Status Completed
Phase Phase 2
Start date May 2010
Completion date December 2012

See also
  Status Clinical Trial Phase
Completed NCT03288675 - Stepped Care aiTBS 2 Depression Study (Ghent) N/A
Completed NCT02989727 - Melancholic Symptoms in Bipolar Depression and Responsiveness to Lamotrigine Phase 4
Completed NCT00000378 - Antidepressant Treatment of Melancholia in Late Life Phase 4
Recruiting NCT04160377 - A Clinical Trial of Fluvoxamine for Melancholia Phase 2